Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexios Matikas

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Breast (Edinburgh, Scotland)|May 10, 2025
Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter studyUna Kjällquist, Nikos Tsiknakis, Balazs Acs, et al.
Breast Cancer Research and Treatment|December 1, 2017
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancerAlexios Matikas, Sara Margolin, Mats Hellström, et al.
Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.
JAMA Oncology|August 29, 2024
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-AnalysisGuillermo Villacampa, Victor Navarro, Alexios Matikas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, Volker Möbus, Richard Greil, et al.
NPJ Breast Cancer|March 7, 2025
Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trialIoannis Zerdes, Alexios Matikas, Artur Mezheyeuski, et al.
The Lancet Regional Health. Europe|September 22, 2025
Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort studyMaria Angeliki Toli, Xingrong Liu, Davide Massa, et al.
British Journal of Cancer|January 26, 2018
Immune gene expression and response to chemotherapy in advanced breast cancerTheodoros Foukakis, John Lövrot, Alexios Matikas, et al.
Oncology Research and Treatment|December 6, 2022
Career and Professional Development for Young OncologistsMaximilian J Mair, Claudia Cardone, Liz Connolly, et al.
NPJ Breast Cancer|November 20, 2021
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility studyIoannis Zerdes, Michele Simonetti, Alexios Matikas, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Breast (Edinburgh, Scotland)|May 10, 2025
Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter studyUna Kjällquist, Nikos Tsiknakis, Balazs Acs, et al.
Breast Cancer Research and Treatment|December 1, 2017
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancerAlexios Matikas, Sara Margolin, Mats Hellström, et al.
Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.
JAMA Oncology|August 29, 2024
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-AnalysisGuillermo Villacampa, Victor Navarro, Alexios Matikas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, Volker Möbus, Richard Greil, et al.
NPJ Breast Cancer|March 7, 2025
Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trialIoannis Zerdes, Alexios Matikas, Artur Mezheyeuski, et al.
The Lancet Regional Health. Europe|September 22, 2025
Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort studyMaria Angeliki Toli, Xingrong Liu, Davide Massa, et al.
British Journal of Cancer|January 26, 2018
Immune gene expression and response to chemotherapy in advanced breast cancerTheodoros Foukakis, John Lövrot, Alexios Matikas, et al.
Oncology Research and Treatment|December 6, 2022
Career and Professional Development for Young OncologistsMaximilian J Mair, Claudia Cardone, Liz Connolly, et al.
NPJ Breast Cancer|November 20, 2021
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility studyIoannis Zerdes, Michele Simonetti, Alexios Matikas, et al.
Pageof 10